Akums Drugs and Pharmaceuticals saw a 5% jump in its stock price after signing an exclusive Master Sales Agreement with South Korea-based Caregen Co., Ltd. The deal gives Akums exclusive rights to package, market, and sell Caregen’s innovative nutraceutical products in India under the Caregen trademark, Akums’ trademark, or its clients’ trademarks.
This strategic partnership is expected to strengthen Akums’ foothold in India’s booming nutraceutical market.
On the trading front, Akums’ stock opened at ₹536.00, reached a high of ₹580.65, and dipped to a low of ₹530.05.
As of 12:34 pm, Akums Drugs shares were trading 5.00% higher at Rs 580.65 on the NSE.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
